Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1097

Similar articles for PubMed (Select 12000204)

1.

Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial.

Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA.

J Clin Psychiatry. 2002 Apr;63(4):308-15.

PMID:
12000204
2.

Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.

Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF.

J Psychiatr Res. 2005 Jan;39(1):43-53.

PMID:
15504423
3.

Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.

Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA.

J Clin Psychiatry. 2002 Mar;63(3):225-31.

PMID:
11926722
4.

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.

Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.

Eur Neuropsychopharmacol. 2004 Dec;14(6):457-70.

PMID:
15589385
5.

The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates?

Fava M, Mallinckrodt CH, Detke MJ, Watkin JG, Wohlreich MM.

J Clin Psychiatry. 2004 Apr;65(4):521-30.

PMID:
15119915
6.
7.

Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression.

Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA.

J Psychiatr Res. 2002 Nov-Dec;36(6):383-90.

PMID:
12393307
8.

Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial.

Brecht S, Courtecuisse C, Debieuvre C, Croenlein J, Desaiah D, Raskin J, Petit C, Demyttenaere K.

J Clin Psychiatry. 2007 Nov;68(11):1707-16.

PMID:
18052564
9.

Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.

Wohlreich MM, Mallinckrodt CH, Prakash A, Watkin JG, Carter WP.

Depress Anxiety. 2007;24(1):41-52.

PMID:
16845641
10.

Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.

Trivedi MH, Pigotti TA, Perera P, Dillingham KE, Carfagno ML, Pitts CD.

J Clin Psychiatry. 2004 Oct;65(10):1356-64.

PMID:
15491239
11.

Duloxetine: a review of its use in the treatment of generalized anxiety disorder.

Carter NJ, McCormack PL.

CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. Review.

PMID:
19480470
12.

Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range.

Mallinckrodt CH, Prakash A, Andorn AC, Watkin JG, Wohlreich MM.

J Psychiatr Res. 2006 Jun;40(4):337-48. Epub 2005 Nov 4.

PMID:
16271726
13.

A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.

Perahia DG, Pritchett YL, Kajdasz DK, Bauer M, Jain R, Russell JM, Walker DJ, Spencer KA, Froud DM, Raskin J, Thase ME.

J Psychiatr Res. 2008 Jan;42(1):22-34. Epub 2007 Apr 18.

PMID:
17445831
14.

Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine.

Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA.

J Clin Psychopharmacol. 2004 Aug;24(4):389-99.

PMID:
15232330
15.

Duloxetine efficacy for major depressive disorder in male vs. female patients: data from 7 randomized, double-blind, placebo-controlled trials.

Kornstein SG, Wohlreich MM, Mallinckrodt CH, Watkin JG, Stewart DE.

J Clin Psychiatry. 2006 May;67(5):761-70.

PMID:
16841626
16.

Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.

Nierenberg AA, Greist JH, Mallinckrodt CH, Prakash A, Sambunaris A, Tollefson GD, Wohlreich MM.

Curr Med Res Opin. 2007 Feb;23(2):401-16.

PMID:
17288694
17.

Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy in U.S. Hispanic and majority Caucasian patients.

Lewis-Fernández R, Blanco C, Mallinckrodt CH, Wohlreich MM, Watkin JG, Plewes JM.

J Clin Psychiatry. 2006 Sep;67(9):1379-90.

PMID:
17017824
18.

Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.

Cowen PJ, Ogilvie AD, Gama J.

Curr Med Res Opin. 2005 Mar;21(3):345-56. Review.

PMID:
15811202
19.

Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial.

Rynn M, Russell J, Erickson J, Detke MJ, Ball S, Dinkel J, Rickels K, Raskin J.

Depress Anxiety. 2008;25(3):182-9.

PMID:
17311303
20.

Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.

Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM.

Curr Med Res Opin. 2007 Jun;23(6):1303-18. Epub 2007 Apr 27.

PMID:
17559729
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk